News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
3,058 Results
Type
Article (776)
Company Profile (2)
Press Release (2280)
Section
Business (1243)
Career Advice (20)
Deals (168)
Drug Delivery (10)
Drug Development (586)
Employer Resources (10)
FDA (84)
Job Trends (171)
News (1930)
Policy (144)
Tag
Academia (10)
Alliances (184)
ALS (2)
Alzheimer's disease (4)
Approvals (85)
Artificial intelligence (3)
Bankruptcy (2)
Best Places to Work (110)
BIOSECURE Act (2)
Biotechnology (1)
Breast cancer (1)
Cancer (8)
Cardiovascular disease (2)
Career advice (15)
CAR-T (5)
Cell therapy (17)
Clinical research (407)
Collaboration (5)
Compensation (2)
COVID-19 (13)
CRISPR (15)
C-suite (9)
Cystic fibrosis (30)
Data (7)
Diabetes (3)
Diagnostics (5)
Diversity, equity & inclusion (2)
Drug discovery (3)
Drug pricing (9)
Duchenne muscular dystrophy (1)
Earnings (343)
Editorial (2)
Employer branding (6)
Employer resources (8)
Events (439)
Executive appointments (12)
FDA (98)
Funding (10)
Gene editing (28)
Gene therapy (34)
GLP-1 (18)
Government (28)
Guidances (2)
Healthcare (42)
Huntington's disease (1)
IgA nephropathy (2)
Immunology and inflammation (4)
Infectious disease (13)
Intellectual property (1)
Interviews (3)
IPO (54)
Job creations (67)
Job search strategy (13)
Labor market (2)
Layoffs (2)
Leadership (1)
Legal (18)
Lung cancer (2)
Manufacturing (6)
Medical device (14)
Medtech (14)
Mergers & acquisitions (115)
Metabolic disorders (7)
Neurodegenerative disease (3)
Neuroscience (10)
NextGen: Class of 2025 (50)
Non-profit (14)
Now hiring (1)
Obesity (4)
Opinion (12)
Pain (19)
Parkinson's disease (1)
Partnered (1)
Patents (1)
People (606)
Pharmaceutical (1)
Phase I (145)
Phase II (225)
Phase III (155)
Pipeline (14)
Policy (9)
Postmarket research (18)
Preclinical (34)
Radiopharmaceuticals (1)
Rare diseases (61)
Real estate (57)
Recruiting (4)
Regulatory (127)
Research institute (5)
Resumes & cover letters (5)
RSV (1)
Schizophrenia (1)
Series A (4)
Sickle cell disease (25)
Special edition (1)
Startups (35)
Supply chain (1)
Tariffs (4)
The Weekly (11)
Vaccines (6)
Venture capitalists (1)
Weight loss (3)
Date
Today (1)
Last 7 days (4)
Last 30 days (16)
Last 365 days (237)
2025 (98)
2024 (270)
2023 (222)
2022 (231)
2021 (254)
2020 (260)
2019 (197)
2018 (183)
2017 (221)
2016 (137)
2015 (210)
2014 (79)
2013 (67)
2012 (88)
2011 (122)
2010 (67)
Location
Africa (13)
Alabama (1)
Asia (86)
Australia (19)
California (18)
Canada (6)
China (7)
Colorado (1)
Europe (487)
Illinois (3)
Maryland (6)
Massachusetts (111)
Montana (1)
New Hampshire (2)
New Jersey (2)
New York (1)
North Carolina (8)
Northern California (6)
Ohio (2)
Pennsylvania (4)
South America (13)
Southern California (8)
Texas (1)
United States (159)
Utah (1)
Washington State (4)
3,058 Results for "vertex".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Earnings
Vertex Shrugs Off Q1 Miss With ‘Strong’ Journavx Launch, Encouraging Pipeline Position
Vertex has recorded some 25,000 prescriptions for Journavx since its January approval and is in the process of getting big PBMs to cover the non-opioid pain drug.
May 6, 2025
·
2 min read
·
Tristan Manalac
Diabetes
Vertex Cuts Diabetes Asset, but Analysts Keen on Phase III Option
Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge loss for Vertex given that the company has a more advanced type 1 diabetes candidate in zimislecel.
March 31, 2025
·
4 min read
·
Annalee Armstrong
Pain
Vertex’s Journavx Changes the Pain Treatment Landscape But Opioids Here to Stay
Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a growing number of alternative approaches. Their ultimate uptake, however, remains to be seen.
February 24, 2025
·
9 min read
·
Tristan Manalac
Pain
AlgoTx Stumbles in Non-Opioid Pain Trial Following Vertex’s Journavx Approval
AlgoTherapeutix blames a “strong placebo effect” for the mid-stage failure for its pain gel ATX01, but the company still believes in the promise of its candidate as Vertex Pharmaceuticals’ first-in-class drug Journavx opens up the non-opioid space.
February 18, 2025
·
3 min read
·
Tristan Manalac
Pain
Vertex Eyes Expansive, Easy Access for Journavx in Coming Weeks
Vertex expects to make the newly approved non-opioid pain medicine Journavx available by the end of February.
February 11, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Vertex to Participate in Upcoming Investor Conferences
May 15, 2025
·
2 min read
Legal
HHS Says Vertex is ‘Grasping at Straws’ With Casgevy Fertility Suit
Along with its gene editing therapy Casgevy, Vertex is offering fertility preservation support for its patients—a program that the HHS claims violates anti-kickback statutes.
January 16, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Vertex Reports First Quarter 2025 Financial Results
May 5, 2025
·
20 min read
Gene therapy
Vertex Abandons AAV as Gene Therapy Space Weathers Difficulties
The cell and gene therapy space in recent months has hit several speedbumps, including layoffs, dropped drugs and discontinued partnerships.
May 5, 2025
·
2 min read
·
Tristan Manalac
Pain
Vertex Dips on Mixed Phase II Data for Non-Opioid Pain Therapy
Vertex Pharmaceuticals’ investigational non-opioid analgesic suzetrigine failed to outperform placebo. Investors voiced their concerns as the company’s share price fell 13% in premarket trading.
December 19, 2024
·
2 min read
·
Tristan Manalac
1 of 306
Next
